Literature DB >> 8811431

Fast determination of low-level cytochrome P-450 1A1 activity by high-performance liquid chromatography with fluorescence or visible absorbance detection.

I Leclercq1, J P Desager, C Vandenplas, Y Horsmans.   

Abstract

A method to determine the activity of the cytochrome P-450 1A1 enzyme, by measuring 7-ethoxyresorufin-O-deethylase (EROD) activity using high-performance liquid chromatography (HPLC) with fluorescence or with visible absorbance detection of resorufin, is described. The lowest quantifiable activity (0.2 pmol/mg min) is obtained by incubation of 0.3 mg of human duodenal microsomal proteins using HPLC fluorescence detection. Using HPLC with visible absorbance detection, sensivity was ten times lower. However, the equipment for this last method is available in most laboratories. The use of both HPLC assays allows determination of the low EROD activity level in samples of small size, such as two or three human duodenal biopsies obtained by routine endoscopy. These methods will be a useful tool to study the role of drug intestinal metabolism by cytochrome P-450 1A1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8811431     DOI: 10.1016/0378-4347(95)00543-9

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  3 in total

1.  Pelargonidin activates the AhR and induces CYP1A1 in primary human hepatocytes and human cancer cell lines HepG2 and LS174T.

Authors:  Alzbeta Kamenickova; Eva Anzenbacherova; Petr Pavek; Anatoly A Soshilov; Michael S Denison; Pavel Anzenbacher; Zdenek Dvorak
Journal:  Toxicol Lett       Date:  2013-02-16       Impact factor: 4.372

2.  The algal hepatoxoxin okadaic acid is a substrate for human cytochromes CYP3A4 and CYP3A5.

Authors:  Fujiang Guo; Tianying An; Kathleen S Rein
Journal:  Toxicon       Date:  2009-08-20       Impact factor: 3.033

3.  A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat.

Authors:  Mats O Magnusson; Mats O Karlsson; Rikard Sandström
Journal:  Pharm Res       Date:  2006-03-15       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.